Last reviewed · How we verify
CGB-400
CGB-400 is designed to target and inhibit a specific pathway involved in disease progression, though the exact mechanism is not publicly disclosed.
At a glance
| Generic name | CGB-400 |
|---|---|
| Sponsor | CAGE Bio Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The drug aims to modulate a key biological process that contributes to the development or worsening of the targeted condition. The specific details of the mechanism are proprietary and have not been fully revealed.
Approved indications
Common side effects
Key clinical trials
- CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea (PHASE2)
- An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
- CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes (PHASE1)
- CGB-400 for the Reduction of Facial Redness (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |